Table 2 bassline comparisons after PSM between the case and control groups.

From: Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case–control study for a rare cancer entity

 

APC n = 130

CCPC n = 130

P value

n

%

n

%

Age (years) medium (IQR)

72.00 (66.00–78.00)

72.00 (65.00–79.00)

0.89

 Diagnosis year

    

0.14

 1975–1998

114

87.7

121

93.1

 

 1999–2019

16

12.3

9

6.9

 

Race

    

1.00

 White

118

90.8

118

90.8

 

 Non-white

12

9.2

12

9.2

 

 UN

2792

.7

/

/

/

Marriage

    

0.76

 Married

94

72.3

99

76.2

 

 Single

32

24.6

27

20.8

 

 UN

4

3.1

4

3.1

 

Income

    

0.55

 < $75,000

20

15.4

21

16.2

 

 ≥ $75,000

14

10.8

9

6.9

 

 UN

96

73.8

100

76.9

 

Home

    

0.22

 Big city

16

12.3

9

6.9

 

 Small city

14

10.8

20

15.4

 

 UN

100

76.9

101

77.7

 

Gleason score

    

1.00

 ≤ 6

/

/

/

/

 

 7–10

/

/

/

/

 

 TURP

/

/

/

/

 

 UN

130

100

130

100

 

PSA

    

1.00

  < 98.0 ng/ml

/

/

/

/

 

  ≥ 98.0 ng/ml

/

/

/

/

 

 UN

130

100

130

100

 

Seer-Stage

    

0.14

 Localized and regional

22

16.9

14

10.8

 

 Distant

0

0

2

1.5

 

 UN

108

83.1

114

87.7

 

Radiation

    

0.79

 Yes

37

28.5

39

30.0

 

 No/UN

93

71.5

91

70.0

 

Surgery

    

1.00

 Yes

86

66.2

86

66.2

 

 No/UN

44

33.8

44

33.8

 

Systemic therapy

    

0.32

 Yes

0

0

1

.8

 

 No/UN

130

100.0

129

99.2

 

CSM

    

 < 0.05

 Alive or other cause of death

94

72.3

76

58.5

 

 Dead

36

27.7

54

41.5

 

OM

    

 < 0.01

 Alive

12

9.2

1

.8

 

 Dead

118

90.8

129

99.2

 

 Survival time (mo) medium (IQR)

88.00 (41.75–164.00)

57.50 (25.50–137.50)

 < 0.01

  1. CCPC = Clear cell adenocarcinoma of the prostate; APC = acinar carcinoma of the prostate; CSM = cancer-specific mortality; OM = overall mortality; PSM = propensity score matching.